Canada’s Inflation Rate Ticked Up To 1.9% In January
Inflation across Canada rose slightly to an annualized rate of 1.9% in January but remains below the central bank’s 2% target. Statistics Canada reports that the Consumer Price Index (CPI) rose 1.9% year-over-year in January, following an increase of 1.8% in December. Most of January’s gain was due to higher energy prices, which rose 5.3% in January following a 1% increase in December, driven by higher prices for gasoline and natural gas.Prices at the pump increased 8.6% on a year-over-year basis in January. Excluding gasoline, inflation in Canada rose an annualized 1.7% during the year’s first month.Offsetting higher prices for gasoline and natural gas to heat homes was continued downward pressure exerted by the goods and services tax break introduced this past December. Prices for food sold at grocery stores fell 0.6% on a year-over-year basis in January, the first yearly decrease since May 2017, said Statistics Canada. At the same time, prices for food purchased from restaurants declined 5.1% year over year, which is more than triple the previous record decline of 1.6%.Canadians also paid less for alcoholic beverages purchased from stores (down 3.6%) in January compared with a year earlier.Across the country, inflation rose the most in the provinces of Manitoba and Saskatchewan during January, driven by higher energy prices. The Bank of Canada targets inflation at an annualized rate of 2%.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


